RE:RE:RE:RE:RE:RE:Huge volume Yes, MDGL is starting a Phase 3 for NASH has $484 million cash.
TH is not equipped to take on the whole NASH space unless we get stunning results, an excellent plan delivered and do a large capital raise at a much higher share price.
bfw
palinc2000 wrote: When I look at the amount of cash on hand (200 million US Dollars)at Genfit plus the fact that they are raising an unspecified amount in a private placement in Europe amd an a concurrent Offering in the US I am thinking that maybe going after the whole Nash market(not just Hiv Nash) alone for TH might be too big of an undertaking .....So maybe they would try to out license Egrifta in exchange for a major conducting a Phase 3 for Nash in return for a 20% or so royalty,
That would still leave room to do an Offering to acquire the next Taimed drug or another late stage drug
WARNING WARNING WARNING
All subject to getting a patent extension for Egrifta but I am 100 % sure that Luc does not need this board to remind him
Wino115 wrote: Prospectus lists - prepare for commercialiation of elafibranor, phase 3, global phase 3, some future research. So if TH does an offereing to raise capital, they do need to have a sensible use of proceeds. NASH Ph3 would do it as would the next Taimed drug. Of course, it dilutes all of us if there is no need for the cash. But I think we all agree, just highlighting the opportunity to US investors who seem to follow and value biotech higher than in most other markets, possibly getting a few more US analysts following it, etc... would all be a positive development.